Adagene (ADR) (ADAG)
Develops antibody cancer immunotherapies and licenses tumor-activated masking technology.
$2.98
vs last close−0.25 (−7.74%)
In millions of USD, except per-share figures
| In millions | Q3 FY22Sep 2022 | Q4 FY22Dec 2022 | Q1 FY23Mar 2023 | Q2 FY23Jun 2023 | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q4 FY24Dec 2024 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 3 | 9 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 2 |
| Cost of revenue | 0 | 3 | 0 | 9 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Gross profit | 3 | 0 | 9 | 17 | 0 | 0 | 0 | −1 | −1 | 0 | 7 | 1 |
| 19 | 19 | 10 | 10 | 9 | 9 | 9 | 9 | 27 | 15 | 13 | 18 | |
| Research & development | 18 | 18 | 11 | 11 | 8 | 8 | 7 | 7 | 20 | 12 | 10 | 14 |
| 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 3 | 4 | |
| Selling & marketing | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 0 | 0 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −18 | −18 | −3 | −3 | −9 | −9 | −9 | −9 | −27 | −16 | −6 | −17 |
| 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 0 | |
| Interest income | 0 | 0 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 |
| Interest expense | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −3 | 0 | 0 | 0 |
| Income before tax | −16 | −16 | −1 | −1 | −8 | −8 | −9 | −9 | −25 | −14 | −4 | −16 |
| Income tax expense | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Net income from continuing operations | −16 | −16 | −2 | −2 | −7 | −7 | −9 | −9 | −25 | — | −4 | −16 |
| Net income | −16 | −16 | −2 | −2 | −7 | −7 | −9 | −9 | −25 | −14 | −4 | −16 |
| EPS, basic | −$0.47 | −$0.47 | −$0.06 | −$0.06 | −$0.21 | −$0.21 | −$0.24 | −$0.24 | −$0.71 | −$0.36 | −$0.11 | −$0.36 |
| EPS, diluted | −$0.47 | −$0.47 | −$0.06 | −$0.06 | −$0.21 | −$0.21 | −$0.24 | −$0.24 | −$0.71 | −$0.36 | −$0.11 | −$0.36 |
| Weighted average shares, basic | 34 | 34 | 33 | 33 | 35 | 35 | 35 | 35 | 37 | 38 | 38 | 45 |
| Weighted average shares, diluted | 34 | 34 | 35 | 35 | 35 | 35 | 35 | 35 | 37 | 38 | 38 | 45 |
| EBITDA | −18 | −18 | −2 | −2 | −9 | −9 | −9 | −9 | −23 | −15 | −5 | −16 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| EBIT | −18 | −18 | −3 | −3 | −9 | −9 | −9 | −9 | −23 | −16 | −6 | −17 |